Frontline Pembrolizumab Regimen Approved in Europe for Squamous NSCLC

March 14, 2019 – The European Commission has approved pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel for the frontline treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC). The approval is based on findings from the phase III KEYNOTE-407 trial, in which pembrolizumab plus chemotherapy demonstrated a 36% reduction in the risk of death compared with chemotherapy alone … (leggi tutto)